Novartis study shows migraine support in the workplace can improve employee quality of life

Sep 05, 2019
  • Results from the Migraine Care support program show that employer-initiated educational and counselling support cut migraine-related disability by more than half after 6 months[1]     
  • Migraine Care is a pilot employee support program offered by Novartis to its employees and their family members in Switzerland 
  • The program encourages managers and employees to speak up about migraine, and includes free personalized coaching calls with an independent telemedicine provider 
  • A study assessing the impact of Migraine Care is being presented at the 19th Congress of the International Headache Society (IHC), 5-8 September 2019 

Basel, September 5, 2019 – Caroline Barth, Head of Pharma People and Organization at Novartis said: “Migraine predominantly affects people in their prime working years, resulting in a substantial impact on workplace productivity. However, the impact of migraine and headaches at work is often unseen or underestimated by employers and can be underplayed by employees in order to hold on to their jobs. One of the strategic priorities at Novartis is to unleash the power of people, encouraging them to be the best they can be. Supporting people with conditions like migraine and providing education in the workplace can result in significant benefits for both employee and employer, as demonstrated by our Migraine Care pilot program.”

Infographic[1]

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Migraine Care
Migraine Care is a pilot program created by Novartis, in collaboration with patient groups and leading experts in neurology, telemedicine and digital medicine, to provide a complimentary, independent, third-party service for all Swiss-based Novartis associates living with migraine to improve their quality of life. The program aims to raise awareness of migraine in the workplace and provide free coaching to Novartis associates living with migraine to empower them in the management of the disease. Novartis is exploring opportunities to work with other employers who are interested in supporting their employees and family members living with migraine.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis or follow @NovartisNews for the latest News & Media Updates at https://twitter.com/novartisnews.
For Novartis multimedia content, please visit www.novartis.com/news/media-library.
For questions about the site or required registration, please contact [email protected].

 
Reference
[1]   Schaetz L, Pathak P, Fang J et al. Impact of an employer-provided migraine-coaching program on burden and patient engagement: results from interim analysis. Abstract presented at the 19th Congress of the International Headache Society (IHC), 5-8 September 2019, Dublin, Ireland. 

# # #

Novartis Global External Communications
E-mail: [email protected]

Antonio Ligi
Novartis Global External Communications
+41 61 324 1374 (direct)
[email protected]

 

Eric Althoff
Novartis US External Communications
+1 646 438 4335 (direct)
[email protected] 
Rachel Fink
Novartis Global Pharma Communications
+41 61 324 8245 (direct)
[email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Central   North America  
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258
Thomas Hungerbuehler +41 61 324 8425    
Isabella Zinck +41 61 324 7188    

             

# # #